Deep Evolution DD — 2026-05-25
2026-05-25 19:16 · 11.3 KB
Date: 2026-05-25
Type: Evolve
Stocks: NEC Corporation (6701.T), Yamato Kogyo (5444.T), Nihon Kohden (6849.T)
Methodology: T-Glass Supply Chain Bottleneck Analysis + ReACT verification
Summary
Three stocks with oldest data_date (2026-04-14) refreshed with full-year FY2026 results now available. Selection rationale: NEC has sovereign AI catalysts advancing; Yamato Kogyo had FY2026 H1 earnings catalyst; Nihon Kohden needed catalyst dates added. All three status: HOLD — thesis intact with updated conviction levels.
1. NEC Corporation (6701.T) — HOLD ✅
Thesis Status
HOLD — Three major catalysts confirmed since April; thesis significantly strengthened.
What Changed Since April 2026
| Metric | April 2026 | May 2026 | Change |
|---|---|---|---|
| PE (TTM) | 27.3x | 20.9x | ↓ Improved (earnings +56%) |
| Forward PE | N/A | 17.45x | New |
| P/B | 2.41x | 4.15x | Revised upward |
| ROE | 8.8% | 12.1% | ↑ Structural improvement |
| Op Margin (non-GAAP) | 7.6% | 11.1% | ↑ +350bps |
| Dividend Yield | 0.8% | 0.9% | ↑ ¥38/share |
| Market Cap | N/A | ¥5.47T | New |
| Stock Price | ~¥4,011 | ¥4,105 | +2.3% |
Three New Catalysts (not in April data)
1. NEC cotomi v3 → Digital Agency Gennai (March 2026) — cotomi selected as one of 7 domestic LLMs for Japan's "Gennai" government AI platform. Deployed to ~180,000 government staff across all ministries. This is the first commercial-scale government contract for NEC's AI revenue thesis.
2. Anthropic Strategic Partnership (April 23, 2026) — NEC became Anthropic's first Japan-based global partner. Claude integrated into NEC's BluStellar Scenario platform for 30,000 NEC employees and external customers. Joint development for financial, manufacturing, and local government AI solutions.
3. CSG Systems Acquisition Completed (May 14-15, 2026) — NEC completed $2.9B (~¥450B) acquisition of CSG Systems. Netcracker + CSG = one of the world's largest telco SaaS platforms (~$1B+ ARR). Adds global recurring revenue but increases leverage.
FY2026 Results (Year Ended March 31, 2026)
- Revenue: ¥3,582.7B (+4.7%; +9% organic ex-divestitures)
- Non-GAAP Operating Profit: ¥397.2B (+27.6%), margin 11.1% (+200bps) — record margin
- Net Income: ¥270.2B (+54.3%) — record high
- EPS: ¥202.95 (post 5-for-1 split, April 2025)
- Dividend: ¥38/share (was ¥28; guided ¥40 in FY2027)
FY2027 Guidance
- Revenue: ¥3,500B (-2.3% — planned exit from low-margin hardware)
- Non-GAAP OP: ¥420B (+5.7%), margin target 12%
- BluStellar DX revenue target: ¥840B
Anti-Pattern Checks
- ✅ Peak Earnings Trap: Not applicable — IT services, structural improvement
- ✅ Concept Stock: AI revenue <1% of total BUT cotomi now has confirmed government contract and growing enterprise deployments. Timeline to material revenue: FY2028-2030.
- ✅ Capacity Hangover: N/A (software)
Valuation Guardrails
- PB 4.15x: High for IT sector but justified by ROE improvement (8.8%→12.1%) and structural earnings growth. Not a cyclical — no peak-PB guardrail breach.
- D/E will rise post-CSG acquisition. Monitor at FY2027 Q1.
Inversion
Thesis breaks if: (1) NEDO formal award excludes the SoftBank/NEC JV; (2) CSG integration costs exceed $2.9B; (3) cotomi loses Gennai renewal to a foreign LLM provider; (4) FY2027 non-GAAP OP misses ¥420B target.
2. Yamato Kogyo Co., Ltd. (5444.T) — HOLD ✅
Thesis Status
HOLD — JV thesis strongly confirmed by FY2026 results. Stock -22% since April = cheaper entry.
What Changed Since April 2026
| Metric | April 2026 | May 2026 | Change |
|---|---|---|---|
| PE (on actual net income) | 16.4x | 8.7x | ↓ Stock fell + earnings surged |
| Forward PE | 13.8x | 8.0x | ↓ Cheaper |
| P/B | 1.26x | 1.25x | Stable |
| Op Margin (standalone) | 4.0% | 2.8% | ↓ Standalone weak |
| Dividend Yield | 3.3% | 3.21% | Stable |
| Market Cap | ¥725B | ¥563B | ↓ Stock fell |
| Stock Price | ~¥16,000 | ¥12,460 | -22% |
FY2026 Results (Year Ended March 31, 2026)
- Revenue: ¥160.4B (-4.7%) — domestic H-beam demand weak
- Standalone Operating Profit: ¥4.5B (-60.9%) — Japanese/ASEAN ops impacted by China dumping
- Ordinary Profit: ¥65.2B (+19.9%) — Nucor-Yamato JV equity method income
- Net Income: ¥62.4B (+96.0%) — includes one-time policy-share sales (non-recurring)
- Dividend: ¥400/share (maintained)
Nucor-Yamato JV — UPGRADED
Nucor Q1 2026 (April 28, 2026):
- Record steel shipments: 7 million tons (+20% from Dec 2025 backlog)
- Structural steel backlogs at "historic levels" — customers "busier than at any point in recent decades"
- Section 232 tariff restructure (April 6, 2026) further shields domestic US producers from imports
- This directly drove Yamato's ordinary profit surge. The thesis is confirmed.
FY2027 Guidance
- Ordinary Profit: ¥68B (+4.2%) — guided conservatively (analyst consensus ¥76.8B is more bullish)
- Net Income: ~¥47B (-25%) — because FY2026 included non-recurring policy-share gains
- Dividend: ¥400/share maintained
- Revenue: ~¥166B (+3%)
Note: The -25% net income guidance is a de-risking of one-time items, NOT an underlying deterioration. The ordinary profit (which shows JV income) growing +4.2% is the real signal.
Anti-Pattern Checks
- ✅ Peak Earnings Trap: Standalone OP at trough (-61%), NOT a peak. JV ordinary profit +20% is sustainable structural income.
- ⚠️ Capacity Hangover: Chinese EAF overcapacity flooding ASEAN — real risk to Thai/Korean subsidiaries
- ✅ Concept Stock: Not applicable (100% steel)
Valuation Guardrails
- PB ~1.25x: Below 80th percentile for steel cyclicals. PASS.
- FCF ¥40B confirmed from prior data.
Inversion
Thesis breaks if: (1) Nucor-Yamato backlog collapses on US construction slowdown; (2) Section 232 tariffs rolled back; (3) Nucor (51% owner) changes JV distribution policy.
3. Nihon Kohden Corporation (6849.T) — HOLD ⚠️
Thesis Status
HOLD — Mean-reversion slower than expected. FY2026 OpMar missed (7.97% vs 9.2% expected). But FY2027 guidance (+25.4% OP growth) signals the recovery is finally starting. Watch closely.
What Changed Since April 2026
| Metric | April 2026 | May 2026 | Change |
|---|---|---|---|
| PE (TTM) | 13.9x | 20.3x | ↑ Re-rated without EPS growth |
| Forward PE | N/A | 18.9x | New |
| P/B | 1.44x | 1.35x | ↓ Slight compression |
| ROE | 7.1% | 7.1% | Unchanged |
| Op Margin | 9.2% | 7.97% | ↓ MISSED |
| Dividend Yield | 2.1% | 1.92% | ↓ Slight (¥33/¥1,720) |
| Market Cap | N/A | ¥285B | New |
| Stock Price | ~¥1,182 | ¥1,720 | +45.5% |
FY2026 Results (Year Ended March 31, 2026)
- Revenue: ¥235.1B (+4.3%) — growth continuing
- Operating Income: ¥18.7B (-9.5%) → OpMar 7.97% (below 9.2% expectation) ❌
- Ordinary Profit: ¥22.5B (+10.7%) — non-operating income offset
- Net Income: ¥14.5B (+2.9%), EPS ¥85
- Q4 FY2026: Operating profit ¥10.6B (+55.3% YoY) — strong exit momentum ✅
- Dividend: ¥33/share (↑¥1 vs prior year)
Reasons Operating Income Missed
- Wage increases (賃上げ対応) — Japan-wide labor cost inflation
- Rising R&D investment in BEACON 2030 digital health platform
- Increased depreciation from M&A and capex
- Domestic revenue slightly declined (procurement timing vs structural)
FY2027 Guidance — The Recovery Signal
- Operating Profit: ¥23.5B (+25.4%) → implied OpMar ~10%
- Revenue: flat/slight decline — profitability-over-growth strategy
- "Double-digit operating income growth" — management committed
BEACON 2030 reality check: Original target was 15% OpMar by FY2027. FY2027 guidance implies ~10%. The 15% target is now a FY2029-2030 story at best. Thesis needs recalibration: target 10-12% OpMar recovery, not 15%.
US Market Expansion — New Evidence
- Life Scope G7 Patient Monitor: Launched in US market for high-acuity ICU settings
- FDA 510(k) K242750 (June 2025): Software-only Central Station cleared — strategic shift to software-based monitoring
- Digital Health Division (NKC DHS) expanding — AI clinical prediction models, Care Cycle Solution
Anti-Pattern Checks
- ✅ Peak Earnings Trap: Explicit trough story — OpMar 7.97% vs peak 15.1%
- ✅ Capacity Hangover: N/A
- ✅ Concept Stock: N/A
Valuation Guardrails
- PE 20.3x on trough EPS: No longer cheap. Thesis requires FY2027 delivery.
- EV validation: Market cap ¥285B with ¥23.5B operating profit guided = P/OP of 12.1x. Reasonable if recovery materializes.
Inversion
Thesis breaks if: FY2027 operating profit misses ¥23.5B guidance (already missed FY2026 targets). Two consecutive guidance misses = BEACON credibility destroyed. Exit trigger: FY2027 Q1 OpMar below 8.5% annualized.
Risk Flags
NEC (6701.T)
- ⚠️ CSG Integration Risk: $2.9B acquisition adds leverage (D/E will rise from 91% to ~150%+). Integration of two large software platforms has execution risk.
- ⚠️ Concept Stock Flag: Sovereign AI revenue still <1% of total. The thesis is real (cotomi in government AI confirmed) but monetization timeline is FY2028+.
Yamato Kogyo (5444.T)
- ⚠️ ASEAN Capacity Hangover: Chinese EAF steel dumping in ASEAN markets is a real risk to Thai/Korean subsidiaries. Does not affect US JV (tariff-protected) but worth monitoring.
- ⚠️ Standalone P&L Distortion: Investors using operating profit (¥4.5B, -61%) will see a "broken" company. Reality is the JV income (¥65.2B ordinary profit) is the business. PE based on net income (8.7x) is the right metric.
Nihon Kohden (6849.T)
- ⚠️ Valuation Guardrail: PE re-rated from 13.9x to 20.3x without EPS growth. Stock is no longer a "cheap trough play" — the recovery is priced in. FY2027 delivery required to justify current price.
- ⚠️ BEACON 2030 Target Miss: 15% OpMar by FY2027 is unachievable. Recalibrate expectations to 10-12% by FY2027-2028. This is a thesis timing error, not a thesis invalidation.
Sources
- NEC FY2026 results: https://japanir.jp/en/company/company-6701/ir/6701-20260428-03_wp_financial_summary/
- NEC cotomi Gennai: https://www.telecompaper.com/news/nec-llm-selected-for-japanese-govt-gen-ai-evaluation-programme--1564745
- NEC Anthropic: https://www.nec.com/en/press/202604/global_20260423_01.html
- NEC CSG acquisition: https://www.nec.com/en/press/202605/global_20260515_01.html
- Japan AI Foundation Model: https://tech-insider.org/japan-ai-foundation-model-softbank-sony-honda-nec-2026/
- Yamato Kogyo FY2026: minkabu.jp/stock/5444/settlement
- Nucor Q1 2026: https://nucor.com/news-release/nucor-reports-results-for-the-first-quarter-of-2026-122991
- Yamato Kogyo buyback: https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/967010/yamato-kogyo-completes-yen11-26-billion-share-buyback-program/
- Nihon Kohden FY2026: https://www.release.tdnet.info/inbs/140120260512526355.pdf
- NKC Life Scope G7: https://g-medtech.com/news/nihon-kohden-launches-life-scope-g7-patient-monitor-in-the-u-s/
- NKC FDA 510(k): https://www.accessdata.fda.gov/cdrh_docs/pdf24/K242750.pdf
- NKC FY2027 guidance: https://finance.yahoo.co.jp/news/detail/72ae8b7cc74fce72ca01c215caa255a7f556001e
*Research conducted 2026-05-25. All metrics from public sources (Tier 1-2). Financials in JPY.*